{
      "Rank": 48,
      "Acronym": [
            "MSC-ROLE"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Intervention: a previously selected dose of MSCs (Phase IIa) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.",
            "Intervention: A Placebo (infusion vehicle) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate."
      ],
      "ArmGroupInterventionName": [
            "Biological: MSC treatment",
            "Drug: Standard of Care",
            "Drug: Standard of Care",
            "Drug: Placebo"
      ],
      "ArmGroupLabel": [
            "MSC treatment",
            "Placebo"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03917797"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Phase II Clinical Trial to Assess the dose-response and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (MSCs) in Severe Renal Systemic Lupus Erythematosus (SLE)."
      ],
      "BriefTitle": [
            "Mesenchymal Stromal Cells (MSC\u00b4s) in Renal Lupus"
      ],
      "CentralContactEMail": [
            "ffigueroa@uandes.cl",
            "fespinoza@c4c.cl"
      ],
      "CentralContactName": [
            "Fernando F E, MD",
            "Francisco Espinoza, MD"
      ],
      "CentralContactPhone": [
            "+56226181455",
            "+56226181008"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Lupus Erythematosus, Systemic",
            "Lupus Glomerulonephritis"
      ],
      "ConditionAncestorId": [
            "D000003240",
            "D000001327",
            "D000007154",
            "D000009393",
            "D000007674",
            "D000014570"
      ],
      "ConditionAncestorTerm": [
            "Connective Tissue Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Nephritis",
            "Kidney Diseases",
            "Urologic Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC17",
            "BC20",
            "All",
            "BXS",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Skin and Connective Tissue Diseases",
            "Immune System Diseases",
            "All Conditions",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Lupus Erythematosus, Systemic",
            "Lupus Glomerulonephritis",
            "Glomerulonephritis",
            "Lupus Glomerulonephritis",
            "Glomerulonephritis"
      ],
      "ConditionBrowseLeafId": [
            "M10329",
            "M11490",
            "M10330",
            "M8183",
            "M5616",
            "M3781",
            "M9352",
            "M9850",
            "M16471",
            "T3523",
            "T2525"
      ],
      "ConditionBrowseLeafName": [
            "Lupus Erythematosus, Systemic",
            "Nephritis",
            "Lupus Nephritis",
            "Glomerulonephritis",
            "Connective Tissue Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Kidney Diseases",
            "Urologic Diseases",
            "Lupus Nephritis",
            "Glomerulonephritis"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000005921",
            "D000008181",
            "D000008180"
      ],
      "ConditionMeshTerm": [
            "Glomerulonephritis",
            "Lupus Nephritis",
            "Lupus Erythematosus, Systemic"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [
            "Superiority trial comparing MSCs versus Placebo in SLE patients with severe renal disease receiving Standard of Care treatment."
      ],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [
            "Masking for patients, physicians providing patient care and outcome assessors."
      ],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "Phase IIa trial of escalating doses of intravenous (i.v.) MSCs in active SLE, followed by a Phase IIb, triple blind, controlled assessment of the selected MSC dosing versus Placebo, in SLE patients receiving Standard of Care Therapy for Severe Renal Disease,"
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nFulfilling 1997 updated American College of Rheumatology (ACR) Criteria or 2012 SLICC Classification Criteria for SLE\nSeropositive for antinuclear (\u22651:80) and/or anti-DNA antibodies\nFulfilling following criteria for active renal disease:\n\nClass III or IV proliferative disease (ISN/RPS) Renal Biopsy within 12 months plus...\n\nActive Urinary Sediment (> 5 red blood cells/high-power field and/or >8 white blood cells/high-power field and/or cylindruria during the current flare).\n\nUPC ratio \u2265 1\n\nExclusion Criteria:\n\nEstimated GFR < 40ml/min/m2\nAddition during prior 3 months of randomization of: Bolus methylprednisolone or new immunosuppressive drug or intravenous immunoglobulin (IVIG) or Plasmapheresis.\nAddition during prior 6 months of randomization of Cyclophosphamide\nAddition during prior 12 months of randomization of Biological anti-B cell therapy\nCoexisting uncontrolled morbidity; Pregnancy or planned Pregnancy within next 12 months; uncontrolled infection or neoplastic disease. Pending unresolved surgical indication."
      ],
      "EnrollmentCount": [
            "39"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "MSC treatment",
            "MSC treatment",
            "Placebo",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ANeo",
            "All",
            "Infl",
            "AnEm",
            "NeuroAg",
            "Gast",
            "ARhu"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antineoplastic Agents",
            "All Drugs and Chemicals",
            "Anti-Inflammatory Agents",
            "Antiemetics",
            "Neuroprotective Agents",
            "Gastrointestinal Agents",
            "Antirheumatic Agents"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M11280",
            "M13272",
            "M1833",
            "M10901",
            "M10902",
            "M229437",
            "M211896",
            "M248768",
            "M5879",
            "M13273"
      ],
      "InterventionBrowseLeafName": [
            "Mycophenolic Acid",
            "Prednisolone",
            "Methylprednisolone Acetate",
            "Methylprednisolone",
            "Methylprednisolone Hemisuccinate",
            "Prednisolone acetate",
            "Prednisolone hemisuccinate",
            "Prednisolone phosphate",
            "Cyclophosphamide",
            "Prednisone"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Umbilical cord-derived Mesenchymal Stromal Cell",
            "Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate",
            "MSC infusion vehicle"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "MSC treatment",
            "Standard of Care",
            "Placebo"
      ],
      "InterventionOtherName": [
            "Cellistem \u00ae Lupus",
            "Standard of Care for Lupus Nephritis",
            "Placebo (for MSC)"
      ],
      "InterventionType": [
            "Biological",
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Systemic Lupus Erythematosus",
            "Mesenchymal Stromal Cells",
            "Lupus nephritis"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "November 16, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "November 13, 2020"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Universidad de los Andes, Chile"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Santiago de Chile",
            "Santiago de Chile"
      ],
      "LocationContactEMail": [
            "ffigueroa@uandes.cl",
            "jacquelinepefaur@gmail.com"
      ],
      "LocationContactName": [
            "Fernando F E",
            "Jacqueline Pefaur, M.D."
      ],
      "LocationContactPhone": [
            "226181455",
            "+56998221921"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact"
      ],
      "LocationCountry": [
            "Chile",
            "Chile"
      ],
      "LocationFacility": [
            "Cl\u00ednica Universidad de los Andes",
            "Hospital Barros Luco Trudeau"
      ],
      "LocationState": [
            "Regi\u00f3n Metropolitana",
            "Regi\u00f3n Metropolitana"
      ],
      "LocationStatus": [
            "Recruiting",
            "Recruiting"
      ],
      "LocationZip": [
            "7591278"
      ],
      "MaximumAge": [
            "75 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Dose-response and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Renal Systemic Lupus Erythematosus"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Universidad de los Andes, Chile"
      ],
      "OrgStudyId": [
            "Phase II Lupus MSC"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Professor School of Medicine"
      ],
      "OverallOfficialName": [
            "Fernando F E, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Proportion of Patients that achieve Complete (CR) or Partial (PR) Renal Response at Endpoint"
      ],
      "PrimaryOutcomeMeasure": [
            "Achievement of Global Renal Response (GR) at Study Endpoint"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Universidad de los Andes, Chile"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Fernando E. Figueroa MD"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Program Director Translational Research in Cell Therapy"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Proportion of Patients that achieve CR criteria including: 1) Urinary Protein:Creatinine (UPC) ratio < 0.5; 2) estimated Glomerular Filtration Rate (GFR) \u2265 120 ml/min/m2, or at least 80% of baseline; 3) urinalysis < 10 red blood cells (RBC) and no RBC casts per high power field; 4) Prednisone dose \u226410 mg/day.",
            "Proportion of Patients that achieve PR criteria including: 1) reduction of UPC ratio to at least 50% of baseline; 2) estimated GFR \u2265120 ml/min/m2, or at least 80% of baseline; 3) Prednisone dose \u226410 mg/day.",
            "Proportion of Patients that fulfill any of the following criteria for Treatment Failure including: 1) Daily Prednisone dose cannot be reduced \u2264 10 mg at week 24; 2) Daily Prednisone is increased above 10 mg after week 24; 3) Introduction of a new immunosuppressive regimen, not included in the trial; 4) Use of Rituximab prior to month 12.",
            "Proportion of Patients that achieve SRI response, defined as a >4-point reduction in the SELENA-SLEDAI score, no new British Isles Lupus Assessment Group [BILAG] A organ domain score and no more than 1 new BILAG B score, with no worsening in physician's global assessment score versus baseline).\n\nThe Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) is employed for this calculation.(SELENA-SLEDAI score). The SELENA-SLEDAI score addresses 24 descriptors in 9 organ-systems. Disease worsening increases the score that ranges from 0-105.\n\nThe BILAG addresses 97 items in organ-system domains, in an ordinal (A-E) scale, converted to a numerical (0-96) scale for usual calculations.",
            "Average change in Selena Sledai Score in patients and controls",
            "Average hange in BILAG score in patients and controls",
            "Proportion of patients that experience flares as defined in the Selena Flare Index (SFI). Mild/Moderate Flares are defined by change of 3 or more points in the SELENA-SLEDAI score. Severe Flares are defined as an increase in the SELENA-SLEDAI score to more than 12 points",
            "Changes in the levels of disease relevant biomarkers in peripheral blood/plasma, including 1) anti-dsDNA antibodies by ELISA; 2) complement proteins C3/C4 by nephelometry (mg/dL); 3) Percentage of CD4+ T helper cell subpopulations (Th1, Th17, Treg) and 4) B cell subpopulations (Naive, Memory, Transitional) by Flow cytometry; and 5) Cytokine Panel by Luminex, including Tumor Necrosis Factor (TNF) alpha, Transforming Growth Factor (TGF) Beta1, Interleukin (lL) 6, IL-17A, IL-10, B-cell activating factor/B Lymphocyte Stimulator (BAFF/BLys), Monocyte chemoattractant protein-1 (MCP-1/CCL2), C-X-C motif chemokine 10 (CXCL10), Interferon (IFN) gamma."
      ],
      "SecondaryOutcomeMeasure": [
            "Achievement of Complete Renal Response (CR) at Study Endpoint",
            "Achievement of Partial Renal Response (PR) at Study Endpoint",
            "Treatment Failure",
            "Response of SLE Responder Index (SRI).",
            "Selena Sledai",
            "BILAG score",
            "Disease Flares",
            "Biomarker Response"
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 months",
            "12 months",
            "24 weeks and 12 months",
            "12 months",
            "12 months",
            "12 months",
            "12 months",
            "24 weeks and 12 months"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "April 2, 2019"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "November 2020"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 17, 2019"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "April 2, 2019"
      ],
      "StudyFirstSubmitQCDate": [
            "April 13, 2019"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}